Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT03707977
PHASE1/PHASE2

Dual bNAb Treatment in Children

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the impact of two broadly neutralizing antibodies, VRC01LS and 10-1074, on the maintenance of HIV suppression in a cohort of early-treated children in Botswana.

Official title: A Clinical Trial to Evaluate the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana (Dual bNAb Treatment in Children)

Key Details

Gender

All

Age Range

96 Weeks - 7 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2019-06-17

Completion Date

2021-12-03

Last Updated

2026-05-04

Healthy Volunteers

No

Conditions

Interventions

DRUG

ART

ART will not be provided by the study. Participants will continue to receive their ART regimen they were receiving prior to enrolling in the study.

BIOLOGICAL

VRC01LS

Administered by intravenous (IV) infusion

BIOLOGICAL

10-1074

Administered by intravenous (IV) infusion

Locations (2)

Francistown Non-Network CRS

Francistown, Botswana

Botswana Harvard AIDS Institute Partnership CRS Non-Network

Gaborone, Botswana